Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Nov 2008

Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, Takahashi S, Komatsu H, Ikeda K, Yamaguchi M, Suzuki R, Tanimoto M, Hatake K

Abstract excerpt

BACKGROUND: Several biomarkers indicating poor prognosis have been reassessed in patients receiving rituximab combination chemotherapy for diffuse large B-cell lymphoma (DLBCL). However, few studies have investigated outcome in relation to a combination of these biomarkers. In addition, no large-scale studies have reassessed the outcome of patients with CD5-positive DLBCL treated with rituximab. PATIENTS AND...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to CD5 Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Doxorubicin

Share to Lymphoma, Large B-Cell, Diffuse

Share to Prednisone

Share to Rituximab

Share to Vincristine

Source

Identifiers

PMID: 18573805
DOI: 10.1093/annonc/mdn392

Genes

EFS
BCL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.PMID 18573805Read ↗

De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.Semantic proximity Read ↗

Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.Semantic proximity Read ↗

Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases.Semantic proximity Read ↗

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.Semantic proximity Read ↗

Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes.Semantic proximity Read ↗

Expression profiling analysis of the CD5<sup>+</sup> diffuse large B‐cell lymphoma subgroup: Development of a CD5 signatureSemantic proximity Read ↗

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B‐cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximabSemantic proximity Read ↗

Primary cardiac CD5-positive diffuse large B-cell lymphoma:A case report and review of literatureSemantic proximity Read ↗

De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.Semantic proximity Read ↗

Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical useSemantic proximity Read ↗

CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).Semantic proximity Read ↗

Genome-Wide Array-Based Comparative Genomic Hybridization of Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.